Ampio Pharmaceuticals Inc.
AMPE
AMPE was delisted on the 12th of April, 2024.
29 hedge funds and large institutions have $102K invested in Ampio Pharmaceuticals Inc. in 2023 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 2 closing their positions.
1,114% more capital invested
Capital invested by funds: $8.44K → $102K (+$94K)
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
12% more funds holding
Funds holding: 26 → 29 (+3)
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$50.7K |
| 2 |
HF
HRT Financial
New York
|
+$46.5K |
| 3 |
Morgan Stanley
New York
|
+$13.6K |
| 4 |
CFO
CVA Family Office
Denver,
Colorado
|
+$8.15K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$5.61K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$259 |
| 2 |
SS
Sunbelt Securities
Houston,
Texas
|
-$26 |
| 3 |
SCA
Stonebridge Capital Advisors
St Paul,
Minnesota
|
-$15 |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$7 |
| 5 |
CCMW
Cypress Capital Management (Wyoming)
Sheridan,
Wyoming
|
-$5 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MAWCM
26
Mine & Arao Wealth Creation & Management
Campbell,
California
| $7 | – | – | – |
|
|
RFG
27
RFP Financial Group
Atlanta,
Georgia
| $2 | – | – | – |
|
28
Qube Research & Technologies (QRT)
London,
United Kingdom
| $2 | +$3 | +1 | New |
|
|
SCA
29
Stonebridge Capital Advisors
St Paul,
Minnesota
| – | -$15 | -4 | Closed |
|
|
30
Fidelity Investments
Boston,
Massachusetts
| – | -$7 | -2 | Closed |
|
31
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$5 | +2 | New |
|
AMPE Hedge Fund Activity: Q4 2023 in Review
29 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Ampio Pharmaceuticals Inc. (AMPE) for Q4 2023, worth a combined $102K — up 1,114% from $8.44K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new AMPE positions and 2 closed out — a net gain of 3 holders — while 3 added to existing stakes and 3 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $50.7K. The largest seller was UBS Group, cutting an estimated $259.
- 29 institutional investors held Ampio Pharmaceuticals Inc. (AMPE) as of Q4 2023, up from 26 in Q3 2023.
- Funds reported $102K of Ampio Pharmaceuticals Inc. stock for Q4 2023, up 1,114% quarter-over-quarter.
- 5 funds opened new Ampio Pharmaceuticals Inc. positions in Q4 2023 and 2 closed out, a net change of +3 holders.
- The largest Ampio Pharmaceuticals Inc. buyer in Q4 2023 was Susquehanna International Group, an estimated $50.7K added.
- The largest Ampio Pharmaceuticals Inc. seller in Q4 2023 was UBS Group, an estimated $259 sold.
Based on aggregated 13F filings for Q4 2023.